Skip to content

Effects of Remote Ischemic Conditioning on Myocardial Perfusion in Humans

Effects of Remote Ischemic Conditioning on Myocardial Perfusion in Humans

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02230098
Acronym
CONDI-PET
Enrollment
50
Registered
2014-09-03
Start date
2013-08-31
Completion date
2014-10-31
Last updated
2015-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Heart Disease

Keywords

remote ischemic conditioning, ischemic heart disease

Brief summary

Cardiovascular disease is the second leading cause of death in Denmark, and ischemic heart disease accounts for the bulk of it. The purpose of this study is to clarify whether a mechanical method of remote ischemic conditioning in the form of short-term obstruction of the blood supply to the arm, can improve the heart's blood supply in patients with ischemic heart disease. This will be attempted through experiments on patients with ischemic heart disease and experimental animal studies with simulated cardiovascular disease. This study will help to clarify whether remote ischemic preconditioning can be used to treat patients with ischemic heart disease.

Interventions

OTHERRemote Ischemic Conditioning

Sponsors

Leducq Foundation
CollaboratorOTHER
University of Aarhus
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Patients referred for routine myocardial Rb82-PET scanning at Dept. of Nuclear Medicine & PET center, Aarhus University Hospital, Skejby, Denmark. * Able to understand the written patient information and to give informed consent.

Exclusion criteria

* Patients not undergoing Rb82-PET with adenosine stress test. * Strenuous exercise (running, bicycling, fitness), intake of beta-blockers or alcohol intake on the day before and on the day of investigation. * Pregnant/nursing women. * Fertile women not using contraceptives. * Patients in dialysis treatment. * Other concomitant disease or treatment that according to the investigator's assessment makes the patient unsuitable for study participation. * Known type 2 diabetes

Design outcomes

Primary

MeasureTime frameDescription
Changes in myocardial blood flow (MBF)2 hours - Measurements will be done immediately before/after interventionMBF before and after intervention

Secondary

MeasureTime frame
Difference in MBF between ischemic and non-ischemic myocardial territories.2 hours - Measurements will be done immediately before/after intervention
Difference in MBF between patients with and without ischemic heart disease detectable by Rb82-PET.2 hours - Measurements will be done immediately before/after intervention
Cardioprotection by the intervention measured by an increase in myocardial salvage in isolated rabbit hearts studied in a Langendorff model.6 months following last patient last visit
Relation between changes in MBF and myocardial salvage in rabbit hearts6 months following last patient last visit
• Differences in MBF between regions supplied by coronary arteries subsequently undergoing percutaneous intervention (PCI) and regions supplied by arteries not undergoing PCI6 months following last patient last visit

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026